Here are the 10-K annual reports from Kestra Medical Technologies, Ltd. (KMTS) in our archive since June 2025, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-K covers the audited annual report, with the full financial statements, so if you follow KMTS and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full KMTS filings page.
Kestra Medical Technologies, Ltd. is a commercial-stage wearable medical device and digital health company focused on cardiac recovery. Its Cardiac Recovery System platform is anchored by the ASSURE wearable cardioverter defibrillator, which has protected nearly 40,000 patients as of April 30, 2026.
The ASSURE system emphasizes patient comfort and compliance via SensorFit garments and high-fidelity ECG, achieving median wear of more than 23 hours per day. In the 21,612‑patient ACE-PAS study, ASSURE showed a 100% conversion rate for VT/VF events and low false alarms, with a software update targeting further reductions.
Kestra estimates a WCD addressable market of about $10 billion in the U.S. and $14 billion internationally, versus 2025 global WCD revenues of $1.1 billion and only 16% penetration of eligible U.S. patients. Revenue comes primarily from leasing ASSURE as Durable Medical Equipment, supported by Medicare and contracts covering over 290 million U.S. lives. Key risks include a history of net losses, dependence on ASSURE WCD, reliance on limited suppliers, extensive healthcare and fraud‑and‑abuse regulation, identified material weaknesses in internal control over financial reporting, and significant influence from Bain Capital.